Cloud PR Wire

Author: Kathir J

  • ZOOY VAPE Transforms European Wholesale Market with Strategic 48-Hour Delivery Network and Advanced CE-Certified High-Puff Innovations

    The 12-year manufacturing veteran redefines the supply chain by combining duty-paid local inventory in Germany, Spain, and Poland with industry-leading “Triple-Tank” technology.

    SHENZHEN, China – ZOOY VAPE, a recognized innovator in the electronic cigarette manufacturing sector established in 2013, today announced a major strategic expansion of its European operations. The company has officially fully operationalized its logistics “Iron Triangle”—three strategic distribution hubs located in Germany, Spain, and Poland. This move is designed to offer European wholesalers a seamless, duty-paid supply chain with guaranteed 2-to-5-day delivery windows, effectively eliminating the long lead times and customs uncertainties associated with cross-border imports.

    To celebrate this milestone, ZOOY is launching an exclusive “Partner Sample Program,” offering free sample kits to qualified distributors across the EU to demonstrate the quality of its newly certified product line.

    Business Value Analysis: Speed is Cash Flow

    In the highly competitive European vaping market, inventory turnover speed is critical. ZOOY’s new localized infrastructure addresses this head-on, shifting the paradigm from “Importing” to “Local Distribution.”

    For wholesalers in key markets like Madrid, Berlin, Rome, and Warsaw, this logistics upgrade translates into tangible commercial value:

    • Optimized Cash Flow: Partners no longer need to tie up capital in bulk orders that take weeks to arrive from China. ZOOY’s “Just-in-Time” delivery allows for smaller, more frequent restocking cycles.
    • Risk Elimination: All stock in the Spain, Germany, and Poland hubs is fully Duty-Paid. This removes the risk of unexpected customs seizures or tariff fluctuations.
    • Regional Precision:
      • The Spain Hub: Leveraging CTT and DPD carriers, serving Southern and Western Europe (Spain, Portugal, France, Italy) with delivery times as short as 2 days.
      • The Germany & Poland Hubs: Utilizing UPS and DPD, covering Central, Northern, and Eastern Europe, ensuring markets from the Netherlands to Romania receive stock within 3-5 business days.

    Certified Safety: Compliance Backed by Rigorous Testing

    As the demand for large-capacity disposables (Big Puffs) grows, so does the scrutiny on safety and regulatory compliance. ZOOY distinguishes itself by strictly adhering to European standards.

    The company has secured full CE-EMC Certifications for its flagship high-puff models. According to recent test reports from Shenzhen Qiqing Technology Co., Ltd., key models such as the ZOOY VAPOR 22000 have passed stringent testing under standards EN IEC 55014-1:2021 and EN IEC 55014-2:2021. This certification confirms that ZOOY’s advanced electronics meet all electromagnetic compatibility requirements, ensuring battery stability and user safety even in high-wattage devices.

    This commitment to compliance extends across the “High-Puff” range, including the ZOOY king triple 3 in 1 80k, ZOOY 6 in 1 120k, giving distributors the confidence to sell large-capacity devices in regulated markets.

    Product Technology Deep Dive: The “Flavor & Cloud” Revolution

    ZOOY is introducing two groundbreaking technologies to the European market, designed to solve the most common user complaints: flavor fatigue and weak performance.

    1. The “Triple-Tank” System (Featured in ZOOY King TRIPLE 80000): Unlike standard dual-flavor devices that often suffer from cross-contamination, the King TRIPLE 80000 features a revolutionary Independent 3-Tank Architecture.

    • How it Works: The device houses three physically separated e-liquid reservoirs ， each with its own vaporization channel.
    • The Advantage: This ensures flavor mixing. A user can switch from a fruity profile to a mint profile instantly, with each puff tasting crisp and distinct. This innovation effectively combats “vaper’s tongue” (loss of taste sensation), keeping users engaged with the device for longer.

    2. Advanced Mesh Coil Technology (Featured in SHISHA & BLAZE Series): To cater to the “E-Shisha” trend popular in Germany and Poland, ZOOY deploys Quad Mesh and Dual Mesh coil configurations.

    • The Advantage: By increasing the heating surface area, these coils deliver rapid ramp-up times and consistent heat distribution. This results in a legitimate Direct-to-Lung (DTL) experience with dense cloud production and intense flavor reproduction that mimics traditional Shisha, but in a portable format.

    Empowering Brands: Your OEM/ODM Factory Next Door

    ZOOY is more than just a brand; it is a manufacturing powerhouse with a 6,500 square meter facility and over 12 years of experience serving top-tier industry giants like HQD, Smiss, and ALD.

    ZOOY is now opening its Customization Services to European distributors.

    • Market Adaptation: We can tweak flavor profiles to match specific regional preferences (e.g., sweeter notes for the UK, cooler notes for Germany).
    • Private Labeling: Wholesalers can leverage ZOOY’s R&D capability to launch their own compliant brands, utilizing our CE-certified chassis as a foundation.

    “We invite European brands to utilize our factory capabilities,” said the Sales Director. “Whether you need our ready-to-ship stock in 48 hours or a fully customized private label solution, ZOOY is your factory partner next door.”

    Invitation to Partner

    Verified wholesalers and distributors are invited to contact ZOOY immediately to request the latest European Warehouse Stock List and apply for a Free Sample Kit.

    For media inquiries, wholesale catalogs, and sample requests, please contact:

    Brand/Company Name: ZOOY

    Contact Person Name: Mary

    Contact Person Title: Sales Director

    E-Mail: mary@zooyvape.com

    Telephone/WhatsApp: +86 18124062975  

    Address: No. 5 Yonghe Road, Shiyan Town, Bao’an District, Shenzhen, Guangdong Province 518108, China

    Official Website: www.zooyvape.com

    Social Links: https://www.facebook.com/profile.php?id=61581971165186

  • CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China

    SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”), with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.

     

    Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa (HS) and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for the treatment of asthma is also ongoing.

     

    In March 2023, Incyte announced that povorcitinib met the primary endpoint in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. Results showed that after 24 weeks of treatment, compared with vehicle, total body repigmentation of patients treated with povorcitinib once daily was significantly improved. Furthermore, according to the extended Phase 2b trial, longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile[1]. 

     

    In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the Product in China and may consider further initiating clinical development of povorcitinib in China for the treatment of skin-related diseases such as HS and prurigo nodularis in the future.

     

    Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo.

     

    The Product’s inclusion in the list of Breakthrough Therapeutic Drugs is expected to accelerate its development and review process in mainland China. If approved for marketing in China, the Product has the potential to synergize with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and the innovative drug currently under New Drug Application (NDA) review ruxolitinib phosphate cream, helping the product to quickly realize its clinical and commercial value and benefit more patients with skin diseases. Furthermore, if approved, the Product, together with topical ruxolitinib phosphate cream, will provide vitiligo patients with differentiated and comprehensive treatment options.

     

    The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to the Group (excluding Dermavon and its subsidiaries).

     

    About CMS

     

    CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

     

    CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

     

    CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. 

     

    Reference：

    1. Results from a global multi-center Phase 2b clinical trial of the product for non-segmental vitiligo indication can be found on the Incyte official website: https://investor.incyte.com/news-releases/news-release-details/incyte-an…
    2. Datas are from the China Insights Consultancy (CIC) report

     

    CMS Disclaimer and Forward-Looking Statements

     

    This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

     

    This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

     

     

    Media Contact

    Brand: China Medical System Holdings Ltd.

    Contact: CMS Investor Relations

    Email: ir@cms.net.cn

    Website: https://web.cms.net.cn/en/home/

  • Classic American Christmas Atmosphere: Affordable Ways to Wear Heritage Warmth—COOFANDY Red Plaid Series, Continuing Outdoor Culture and Holiday Traditions

    Street lamps are wrapped in gold foil, and the air is filled with the scent of cinnamon and mulled wine. The most touching aspects of December are perhaps these softly glowing everyday moments—and every seasonal wardrobe should include a red plaid flannel shirt steeped in memories.It evokes images of wool blankets stacked by the fireplace, smoke rising from a cabin after a snowfall, and the broad-shouldered silhouette of a father decorating the Christmas tree in an old shirt. The classic red plaid pattern seems to carry the warmth and sounds of the holidays, instantly transporting one back to those American holiday scenes filled with love.

    American festive attire doesn’t have to be expensive.

    When it comes to the origins of red plaid shirts, Filson is undoubtedly a pioneering representative. But classic style is never exclusive to high prices. Today, COOFANDY weaves this American festive spirit into a plush, affordably priced flannel shirt. The classic red-and-black plaid, crafted from a cotton blend, retains a touch of rugged texture while being gentle on the skin. You can casually roll up the sleeves to wrap gifts under the Christmas tree or layer it under a thick coat on a chilly morning, letting the plaid collar peek out subtly.Natural styling scenarios emerge effortlessly: pair it with straight-leg jeans and a pair of well-worn work boots, as if you’ve just returned from a winter walk in the woods; or tuck a pinecone or eucalyptus leaf into the shirt pocket to instantly brighten up your outfit. It captures the winter wardrobe vibes from Friends episodes and resembles the relaxed, familiar looks found in every American family’s Christmas photo album.

    Layering Adds Depth to Festive Style

    For a touch of scholarly refinement, try layering a diamond-patterned knit vest over the shirt. This classic Ivy League look features a V-neck that perfectly reveals the plaid collar and hem, adding both layers and a sense of festive ritual—as if you’re ready to unwrap gifts, sing carols, and share a toast with long-lost family members.

    This Christmas, Dress in Classic Style, Warm a Season of Hearts
    The resurgence of American outdoor traditions isn’t just about trends; it’s about how these timeless pieces resonate with everyday life, especially during seasons like Christmas that call for warmth and ritual. A simple red plaid shirt can accompany you while baking gingerbread cookies, decorating the Christmas tree, or cozying up on the couch to watch old movies.

    There’s no need to chase after expensive heritage brands; affordability can still deliver classic American festive vibes. COOFANDY’s Red Plaid Series has prepared your entire holiday wardrobe. Special Christmas discounts are underway, with select styles up to 50% off. Treat yourself to some warmth or choose a thoughtful gift for someone special.Welcome to the COOFANDY flagship store or Amazon shop to take home your Christmas warmth.

    For more information, please visit the COOFANDY website and Amazon storefront, or connect with COOFANDY on Facebook and Instagram.

    COOFANDY

    Charlotte Liu

    pr@coofandy.com

    New York, US

    https://coofandy.com

  • AVIDLOVE’s Christmas & New Year Collection is Here: Embrace Renewed Romance for the Holidays

    As Christmas bells chime and New Year’s skies light up with fireworks, dressing for the festive season becomes a key part of year-end socializing. The lingerie brand AVIDLOVE has keenly captured this need, launching its limited-edition Christmas & New Year series themed “Holiday Glow.” Inspired by the mantra “New spark, New you,” the collection blends holiday aesthetics with practical design. Coupled with a limited-time 20% discount, it offers consumers stylish, occasion-ready looks brimming with festive spirit.

    Versatility for Every Scene: From Party Glamour to Home Comfort

    This series skillfully combines classic holiday elements with modern design language, making pieces suitable for showcasing charm at social gatherings while also prioritizing comfort and romance for moments spent at home.

    • Velvet Babydoll Nightgown: Crafted from soft, stretch velvet, its deep V-neck and backless detailing exude subtle sensuality. Adjustable features ensure a perfect fit. A gentle yet sophisticated choice for Christmas Eve family gatherings or romantic dates, perfect for keeping or gifting.
    • Red Velvet Christmas Dress:If you’re searching for a standout party piece, this dress is worth considering. Its A-line cut flatters the figure, while the adjustable Santa-style belt adds a thematic touch. Paired with a white faux fur hem, it effortlessly creates a classic Christmas vibe.
    • High-Neck Shaping Bodysuit:Focuses on inner sculpting and comfort. The double-lined fabric feels silky smooth, and the high-elasticity design with convenient bottom snaps allows for easy wear. It provides stable, close-fitting support, whether for everyday layering or under formal attire.
    • Red Babydoll Pajama Set: Made from soft floral lace and mesh, adorned with floral embellishments on the cups. Adjustable straps and a front-opening design add both convenience and beauty.
    • Santa Babydoll Nightgown: Stands out with its more dramatic design. Feather trim, a tied V-neck, and sheer mesh lace come together to present a playful, sensual holiday style, ideal for themed parties or creating an unforgettable Christmas night look.

    Decoding the Trend of Refined Holiday Dressing

    As year-end social activities increase, people’s demands for clothing increasingly emphasize “occasion-specific dressing, attention to detail, and emotional resonance.” The desire is to shine at parties while also pursuing comfort and a sense of ritual during intimate, at-home moments.

    AVIDLOVE’s latest series is a direct response to this trend. The designs balance thematic appeal with everyday wearability, focusing on fabric texture and style diversity to help wearers express their multifaceted charm across different settings.

    Illuminating Every Highlight Moment with Exquisite Design

    The beauty of the holidays blossoms both under the dazzling lights of parties and within the warm, quiet moments at home shared with loved ones. Through its “Holiday Glow” series, AVIDLOVE—leveraging the texture of velvet, the romance of lace, and the considerate shaping of bodysuits—provides head-to-toe styling solutions for parties, home, and dates alike.

    Just as “New spark, New you” conveys, an outfit that harmonizes with the season can not only elevate your overall look but also rejuvenate your spirit, allowing a new radiance to shine through.

    The AVIDLOVE Christmas & New Year limited series is now available on Amazon. Seize this opportunity to select a sparkling gift for yourself or someone special, making this year-end moment even more memorable and full of festive ritual.

    For more information, please visit the AVIDLOVE website and Amazon storefront, or connect with AVIDLOVE on Facebook and Instagram.

    AVIDLOVE

    Dana Li

    pr@avidlove.com

    New York, US

    https://avidlove.com/

  • Cute Guardianship, Warm Companionship: EKOUAER and Arshiner’s Teddy Bear Family Series Lights Up a Cozy Holiday

    As the holiday season approaches, home becomes synonymous with warmth and togetherness. EKOUAER and Arshiner understand this well and have specially launched a family home apparel series themed around soft teddy bear elements this year. Centered around the themes of “Twirl Into Holiday Season” and “Cheers to Cozy Holidays,” they’ve incorporated adorable and cute teddy bear patterns into comfortable home wear, creating a festive look filled with childlike charm and love for the whole family, ensuring that tender family moments are protected by softness.

    EKOUAER: Authentic Licensed Teddy, A Fairy Tale of Luxurious Satin for Kids

    This season, Ekouaer adorns its luxurious satin pajamas with cute teddy bear patterns. The set is made of high-quality silk satin composed of 95% polyester and 5% spandex, offering a silky, lightweight, and skin-friendly touch that provides a luxurious wearing experience at home. The classic turn-down collar button-up shirt and loose-fitting pants design not only make it easy to put on and take off but also facilitate movement. The exclusive licensed design of the teddy bear adds unique fun and collectible value to festive nights, making it a special holiday gift for your lover, mother, or sister, filling home time with surprises and tenderness.

    Arshiner: Plaid Meets Teddy, Creating a Fun and Safe Holiday for Kids

    Arshiner’s teddy bear series cleverly combines classic plaid with playful teddy bear patterns, offering girls a pajama set full of festive spirit. The fabric is a soft and skin-friendly blend of 95% polyester fiber and 5% spandex, ensuring breathability and comfort. Rounded teddy bear patterns are dotted on the classic plaid, paired with a practical full-button design for easy dressing by children. Notably, all pajamas in this series have passed flame-retardant safety tests, providing a warm and cute festive look while adding an extra layer of thoughtful protection for children’s home safety. It’s a reassuring gift for birthdays, Christmas, and New Year.

    Matching Family Styles for a Heartwarming Holiday

    The teddy bear-themed pajama series launched by these two brands pays special attention to harmonious matching of family styles, ensuring a unified and loving look for the whole family’s festive home wear. Whether it’s Arshiner’s classic and safe plaid or Ekouaer’s authentically licensed satin, both feature high-quality fabrics and thoughtful designs, allowing every member of the family to feel comfortable, cute, and warm during the holidays.

    During the Christmas and New Year promotion period, relevant teddy bear series products are eligible for a holiday-exclusive discount of 10%-30% OFF. This is not only a great opportunity to purchase warm gear for your family but also a wonderful gift that carries warmth, safety, and fun.

    This holiday season, let EKOUAER and Arshiner’s teddy bear family series wrap your home in warmth. Together with your beloved family, twirl into a season filled with laughter and warmth under the cute guardianship.

    For more information, please visit the EKOUAER and the Arshiner.

    EKOUAER

    Dana Li

    pr@ekouaer.com

    New York, US

    https://ekouaer.com/

  • CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China

    SHENZHEN, CHINA – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.

     

    With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms.

     

    Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals.

     

    The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients.

     

    More Information about Y-3 for Injection

    The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects.

     

    The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.

     

    On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent.

     

    About Stroke

    According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects.

     

    About CMS

    CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

     

    CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

     

    CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

     

    Reference

    1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.
    2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.

     

    CMS Disclaimer and Forward-Looking Statements

    This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

     

    This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

     

     

    Media Contact

    Brand: China Medical System Holdings Ltd.

    Contact: CMS Investor Relations

    Email: ir@cms.net.cn

    Website: https://web.cms.net.cn/en/home/

  • Must-Have Items for Christmas and New Year! EKOUAER and Arshiner Accompany You to “Twirl Into Holiday Season”

    The jingle of Christmas bells is drawing ever closer, and it’s time to put the New Year’s party checklist on the agenda! To welcome this period brimming with joy and warmth, well-known home apparel brands EKOUAER and Arshiner have meticulously launched a series of holiday essential items. These cover scenarios such as adults’ home wear, children’s outings, and family gifts, aiming to accompany every family through the holidays with comfortable fabrics, festive designs, and thoughtful details.

    EKOUAER: Home Ritual, Interpreting a Cozy Holiday

    This season, EKOUAER adopts the concept of “Cheers to Cozy Holidays”, emphasizing the creation of a warm-as-spring home experience amid the cold winter. Its regular-style home wear uses soft and skin-friendly fabrics, combined with simple and elegant designs, balancing home comfort with a sense of festive ritual.

    The featured rib-knit pajamas this time are made of a rib-knit fabric that is a blend of 95% polyester fiber and 5% spandex, which is soft and elastic. The classic V-neck design paired with wide-leg pants with pockets is both stylish and practical. The red version is particularly suitable for the festive atmosphere and can be worn for home leisure, going out, or traveling. It also makes a thoughtful gift for female relatives and friends.

    At the same time, the brand’s classic women’s satin pajama set has also joined the festive lineup. The burgundy satin has a smooth and skin-friendly texture, being breathable and lightweight. The top can be worn as an outer layer for daily wear, and the loose-fitting bottoms are comfortable for sleep and home leisure. It’s also a great gift option, adding a touch of gentle ritual to festive nights.

    Arshiner: Childlike Charm and Warmth, Lighting Up Festive Outfits

    Arshiner focuses on creating festive wear for children that combines a sense of ritual and comfort. This series pays attention to fabric texture and pattern design, with smooth lines and a comfortable fit at its core, creating home and outdoor wear suitable for long-term wearing.

    For children, Arshiner has launched a girls’ long-sleeved stretchy dress. Made of a stretchy cotton blend fabric, it features an A-line cut that is flowing and lively. The Christmas red and green color scheme is full of festive spirit, and the simple design is easy to match, making it suitable for parties, festivals, and daily wear. It’s a practical and heartfelt festive outfit for girls.

    The boys’ high-neck knitted sweater is made of a blend of 60% viscose fiber and 40% nylon, which is lightweight, soft, and non-irritating to the skin. The slim-fit design provides warmth without being bulky. The red high-neck style is perfect for autumn and winter and can be worn alone or as a layering piece. It’s suitable for school, family gatherings, and various outdoor activities, offering children a wearing experience that combines warmth and style.

    Mark the Discount Period, Don’t Miss Out

    From now until January 5, 2026, many products from EKOUAER and Arshiner are participating in holiday promotions, offering discounts ranging from 10% to 30% off. This is a great opportunity to purchase your favorite items and add warmth to the holidays.

    Consumers can learn more about product details and place orders through the brands’ official Amazon links. Take advantage of the limited-time offers to achieve high-cost-performance shopping and start your Christmas and New Year with comfortable apparel.

    For more information, please visit the EKOUAER and the Arshiner.

    EKOUAER

    Dana Li

    pr@ekouaer.com

    New York, US

    https://ekouaer.com/

  • Christmas Countdown Begins: EKOUAER and Arshiner Illuminate the Heartwarming Holiday Season with Teddy-Themed Parent-Child Pajamas

    As Christmas approaches, the demand for “parent-child ritualistic” consumption in family settings has significantly surged. Teddy home wear, which combines a soft texture, cute designs, and practical functions, has become a popular choice for parent-child outfits during the Christmas season due to its high compatibility with the festive atmosphere, adding warmth and fun to family reunion moments.

    The Rise of a Heartwarming Christmas Style: Teddy-Themed Outfits as a New Trend for Parent-Child Wear

    Nowadays, when it comes to holiday consumption, consumers not only focus on practicality but also seek the dual satisfaction of emotional value and functional attributes. Especially during Christmas, a time that emphasizes family interaction, parent-child clothing is not just a fashion choice but also a carrier for maintaining emotions and recording heartwarming moments. The inherent cuteness of teddy elements complements the warm atmosphere of Christmas perfectly, enabling teddy home wear to stand out from numerous festive items and become a favorite among both parents and children.

    Dual-Brand Collaboration: EKOUAER and Arshiner Interpret Parent-Child Warmth

    In the field of Christmas teddy home wear, two major brands, EKOUAER and Arshiner, have launched products that combine their respective brand characteristics with a festive spirit, targeting adult and children’s groups respectively and fully covering the needs of parent-child outfits.

    EKOUAER Teddy Collection: Adults’ “Comfortable Ritual for the Holidays”

    Centered around the concept of “Gifting or Treating Yourself,” EKOUAER’s teddy home wear continues the brand’s holiday proposition of “Cheers to Cozy Holidays.” Made from soft and skin-friendly fabrics, it features teddy bear patterns and warm color tones, presenting a warm and cute style. The loose and simple silhouette combines home comfort with a festive atmosphere. Whether it’s for a Christmas movie night, home relaxation, or as a gift for relatives and friends, it can simultaneously meet the requirements of practicality, a sense of ritual, and a pleasant experience.

    Arshiner Teddy Collection: Safeguarding Children’s “Safe and Cute Moments”

    Arshiner, which specializes in children’s clothing, has precisely met parents’ demands for “safety + cuteness” with its teddy-themed girls’ pajama set. The fabric, composed of 95% polyester fiber and 5% spandex, is soft and breathable, reducing feelings of stuffiness and itchiness. The design incorporates pink-striped teddy bear patterns, paired with contrasting trim and a full-button front, balancing childlike charm with easy dressing. The product has passed professional flame-retardant tests to ensure children’s safety. The long-sleeved and warm silhouette is suitable for year-round home scenarios, allowing children to be comfortable and happy during Christmas parties or daily play.

    Practicality and a Sense of Ritual Combined: Teddy Outfits as an Excellent Christmas Gift Option

    The essence of Christmas lies in conveying heartfelt wishes, and teddy home wear strikes a perfect balance between “presenting a respectable gift” and “daily practicality.” Matching parent-child styles can create a complete festive look, doubling the warmth in family photos and gatherings. As a gift for relatives, friends, or children, it not only fits the holiday theme but can also be used for a long time, avoiding post-holiday idleness. It is a thoughtful choice that combines heartfelt sentiments with practical value.

    Christmas & New Year Special Offers: A Highly Cost-Effective Time to Make a Purchase

    To help consumers embrace the festive atmosphere with greater ease, EKOUAER and Arshiner have jointly launched a Christmas and New Year promotion. During the event, all items in the Teddy series homewear from both brands are available at special discounts of 10%-30%.

    This Christmas, whether you choose to indulge in a soft and cozy EKOUAER Teddy homewear set for yourself or pick a cute and safe Arshiner Teddy pajama for your child, let the warmth of the season start with what you wear, enveloping every precious moment of family togetherness and truly bringing to life the cozy vision of “Cheers to Cozy Holidays.”

    For more information, please visit the EKOUAER and the Arshiner.

    EKOUAER

    Dana Li

    pr@ekouaer.com

    New York, US

    https://ekouaer.com/

  • Leapfrog Acquisition Corp Announces Pricing of $125,000,000 Initial Public Offering

    SUMMIT, N.J. – Leapfrog Acquisition Corporation (the “Company”) announced today the pricing of its initial public offering of 12,500,000 units at a price of $10.00 per unit. The units are expected to commence trading on December 5, 2025 on the Global Market tier of The Nasdaq Stock Market LLC under the symbol LFACU.

    The Company, which is led by Matthew R. Pollard, Abhay N. Pande and Kevin M. Murphy, is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

    Each unit sold in the offering consists of one Class A ordinary share (an “ordinary share”) and one half of one redeemable warrant with a strike price of $11.50 per ordinary share exercisable within 5 years of the Company completing an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and warrants are expected to be listed on the Global Market tier of The Nasdaq Stock Market LLC under the symbols “LFAC” and “LFACW,” respectively.

    BTIG, LLC is serving as the sole book-running manager of the offering. The underwriters have been granted a 45-day option to purchase up to an additional 1,875,000 units at the initial public offering price to cover over-allotments, if any.

    A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on December 4, 2025. The offering was made only by means of a prospectus, copies of which, when available, may be obtained by contacting BTIG, LLC, 65 East 55 Street, New York, NY 10022, by emailing ProspectusDelivery@btig.com, or by visiting the SEC’s website at www.sec.gov.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Leapfrog Acquisition Corp

    Leapfrog Acquisition Corp is a blank check company organized for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or engaging in any other similar business combination with one or more businesses or entities.

    The Company is led by Chief Executive Officer, Matthew R. Pollard, President and Chief Investment Officer, Abhay N. Pande and Chief Financial Officer, Kevin M. Murphy.

    The Company will prioritize businesses in the international energy supply chain and critical minerals sectors, including their related infrastructure in its search for attractive merger candidates.

    Forward-Looking Statements

    This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the anticipated use of the proceeds of the Company’s initial public offering, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements, including those set forth in the risk factors section of the registration statement and prospectus for the Company’s initial public offering. Copies of these documents can be accessed through the SEC’s website at www.sec.gov. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.

    Media Contact

    Company: Leapfrog Acquisition Corp

    Contact: Media Team

    Telephone: +1-201-379-4200

    LinkedIn: https://www.linkedin.com/company/leapfrog-acquisition-corporation

    Email In the US:

    abhay@leapfrogspac.com

    Email In Asia:

    matt@leapfrogspac.com

    kevin@leapfrogspac.com

     

  • The Future of Bulk Liquid Packaging: Flexitanks Powering a Greener, Smarter Supply Chain

    As global trade faces mounting pressure to reduce costs, cut carbon emissions, and operate more sustainably, a new logistics solution is reshaping the way bulk liquids move around the world — the flexitank. Once seen as a niche alternative, flexitanks are now rapidly becoming the preferred packaging choice for shippers of edible oils, wine, base oils, and industrial liquids, thanks to their ability to combine efficiency, safety, and sustainability.

     

    A Shift Driven by Efficiency and Sustainability

    Traditional packaging systems — such as steel drums, IBCs, or ISO tanks — have long dominated bulk liquid transport. However, these methods come with high packaging and return logistics costs, contamination risks, and inefficient container utilization.

     

    Flexitanks, on the other hand, transform a standard 20-foot or 40-foot shipping container into a high-capacity liquid vessel capable of holding up to 26,000 liters. They require no cleaning, no return shipments, and are made from recyclable, food-grade materials, aligning perfectly with global sustainability objectives.

     

    By using flexitanks, companies can reduce total logistics costs by 20–30%, simplify handling operations, and drastically cut carbon emissions associated with traditional packaging and return transport.

     

    Key Advantages of Flexitanks

    • Cost-Effective Logistics: No need for returnable containers, washing, or storage. Each flexitank is single-use, reducing both capital and operational expenses.
    • Optimized Space Utilization: Flexitanks fill nearly the entire container, improving payload efficiency compared to drums or IBCs.
    • Zero Contamination Risk: Single-use, hermetically sealed liners prevent product cross-contamination and maintain purity.
    • Simplified Operations: Pump-based loading and unloading systems save time, labor, and handling effort.
    • Environmentally Friendly: Lightweight, recyclable materials and reduced backhaul requirements translate into lower carbon emissions.

     

    These advantages have made flexitanks the go-to choice for industries ranging from food and beverage to chemicals and base oils, helping businesses move toward greener, more efficient supply chains.

     

    LAF Technology: Setting Standards in Flexitank Innovation

    Among global flexitank manufacturers, LAF Technology has emerged as a key force driving innovation and reliability. With years of engineering expertise and deep logistical know-how, LAF has established a strong international presence — today, an estimated one in every four flexitanks used worldwide is produced by LAF.

     

    In 2025, the company marked a major milestone with the launch of its Smart Manufacturing Industrial Park, a new-generation production base equipped with digitalized and automated lines. The facility integrates intelligent manufacturing with ESG-focused sustainability, ensuring both product performance and supply stability while aligning with the global path toward sustainable development.

     

    Product Strengths and Applications

    LAF’s flexitanks are built with multi-layer PE and barrier film structures that provide superior strength and oxygen resistance. The reinforced woven outer shell and heat-sealed seams protect against punctures and stress during long-distance transport. Optional features — such as heating pads, oxygen layers, or high-temperature protection — allow LAF flexitanks to handle temperature-sensitive or specialty liquids safely and efficiently.

     

    They are widely applied across multiple sectors:

    • Food & Beverage: edible oils, concentrated juice, wine, syrups, sorbitol, soy sauce, food additives, etc.
    • Industrial Oil: base oil, lubricant, mineral oils, castor oil, glycerin, refined palm oil, transformer oils, white oil, etc.
    • Non-hazardous Chemical: glycol, plasticizers, latex, fertilizers, emulsions, surfactants, paraffin, printing inks, disinfectants, etc.

     

    Shaping the Future of Liquid Logistics

    The transformation of bulk liquid logistics is well underway. As sustainability becomes not just a goal but a necessity, flexitanks stand out as the modern, low-impact, and cost-efficient alternative.

     

    With its robust product technology, global logistics network, and commitment to sustainability, LAF Technology continues to play a defining role in this evolution — helping businesses around the world transport liquids more efficiently, safely, and responsibly.

     

    The future of bulk liquid packaging is flexible, efficient, and sustainable — and flexitanks are leading the way.

     

    Social Links

    LinkedIn: https://www.linkedin.com/company/laf-technology-co-ltd/

    Facebook: https://www.facebook.com/LAFPackaging

    Instagram: https://www.instagram.com/lafflexitank/

     

    Media contact

    Company Name: Qingdao LAF Technology Co., Ltd.

    City, State, Country: Qingdao, Shandong, China

    Address: No. 666, Xingjialing Village, Tongji St. Office, Jimo

    Contact Person: Catherine

    Email: sales@flexitank.net.cn

    Tele: 86-532-66098998

    Website: https://www.laftechnology.com/